Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 8315353 | HLA-DR (HLA-DR) | b cell leukemia | NA | NA | NA | negation | |
| we investigated the differential expression of the hla-dqb gene, using b cell lines laz221 and laz388: laz221, derived from an early b cell leukemia, expresses hla-dr but not hla-dq: laz388, the autologous epstein-barr virus-transformed b cell line, expresses both dr and dq. | |||||||
| 12697248 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | b cell leukemia | NA | hepatitis | NA | unclassified | |
| furthermore, to evaluate the immune surveillance system and the susceptibility to apoptosis, immunohistochemical staining of human leukocyte antigen (hla)-dralpha, cathepsin d, b cell leukemia-2 (bcl-2), bcl-2-associated x protein (bax) and caspase 3 was also performed. | |||||||
| 6969295 | HLA (HLA) | late onset disease | NA | NA | NA | negation | |
| the abnormalities were particularly associated with late onset disease and female sex, but not with hla phenotype or autoantibody production. | |||||||
| 12930852 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | late onset disease | NA | NA | NA | unclassified | |
| extensions for medical purposes, such as to identify susceptibility genes, late onset disease, and human leukocyte antigen (hla) matching, are usually ethically acceptable. | |||||||
| 34580437 | HLA-DRB1*07 | azathioprine | NA | hepatitis | NA | unclassified | |
| NA | |||||||
| 34580437 | HLA-DRB1*03 | azathioprine | NA | hepatitis | NA | unclassified | |
| NA | |||||||
| 34580437 | HLA-DRB1*04 | azathioprine | NA | hepatitis | NA | unclassified | |
| NA | |||||||
| 22389204 | HLA-CLASS II (HLA CLASS II) | immune disease | NA | NA | NA | unclassified | |
| translational opportunities for immune disease monitoring are driving the rapid development of hla class ii tetramer use in clinical applications, together with innovations in tetramer production and epitope discovery. | |||||||
| 3874036 | HLA-A (HLA-A) | iga nephropathies | NA | NA | NA | positive+negation | |
| since non hla-a, b, c, dr phenotype was prevalent in patients who had defective fc-receptor function, whereas a significant correlation was found between fc-receptor impairment and levels of iga immune complexes, it appears likely that circulating blocking factors, possibly related to iga containing immune materials, may impair macrophage function in iga nephropathies. | |||||||
| 3874036 | HLA-DR (HLA-DR) | iga nephropathies | NA | NA | NA | positive+negation | |
| since non hla-a, b, c, dr phenotype was prevalent in patients who had defective fc-receptor function, whereas a significant correlation was found between fc-receptor impairment and levels of iga immune complexes, it appears likely that circulating blocking factors, possibly related to iga containing immune materials, may impair macrophage function in iga nephropathies. | |||||||
Copyright 2024